BI 425809

Drug Profile

BI 425809

Alternative Names: BI425809

Latest Information Update: 05 Feb 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Boehringer Ingelheim
  • Class Antidementias
  • Mechanism of Action Glycine transporter 1 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Cognition disorders

Most Recent Events

  • 29 Jan 2018 Boehringer Ingelheim re-initiates enrolment in a phase II trial for Cognition disorders in Germany, Austria and South Korea (PO) (NCT02832037)
  • 20 Dec 2017 Boehringer Ingelheim re-initiates enrolment in a phase II trial for Cognition disorders (in patients with Alzheimer's disease) in Austria, Finland, Hungary, United Kingdom and Greece (PO) (NCT02788513)
  • 04 Nov 2017 No recent reports of development identified for phase-I development in Cognition-disorders(In volunteers) in Germany (PO, Liquid)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top